Summit Therapeutics Share Discussion Threads

[metis20] 26/1/2018 20:31

Moving up well on NASDQ today - currently equivalent of about 210p

[waterloo01] 26/1/2018 20:25

One for the initiated (and Glyn). One of the criticisms of the 24 week data is the 6 minute walk test. I had a quick look at SRPT data on which they got approval and over the 1st 12 months, the control group actually performed better than the treated group. It was only after 12 months that the 6MWT started to show significant improvement, which become more stark over time as the control group almost all lost the ability to walk!

See graph on page 64

[someuwin] 26/1/2018 20:18

Summit Therapeutics hugely excited after big DMD ‘breakthrough’

[waterloo01] 26/1/2018 20:09

Interview on proactive (can't link via ADVFN)

[waterloo01] 26/1/2018 15:56

A combination of reduced muscle damage and increased utrophin levels offers evidence that ezutromid may help delay the progress of this disease. Management plans to conduct a pivotal study soon that may enable an accelerated or conditional approval in the U.S. and Europe.

If additional data at the 48-week mark confirms ezotromid's efficacy, it will be great news for patients and Summit Therapeutics. It will also be good news for Sarepta Therapeutics because Sarepta obtained certain ex-U.S. licensing rights to ezotromid in 2016. Specifically, it licensed rights in Europe and certain other abroad markets in exchange for $40 million up front, plus up to $522 million in milestones and royalties ranging from a low to high teens percentage of net sales in its licensed territory.

Given the significant sales that Sarepta is already generating by addressing a fairly limited segment of the DMD market, the potential for Summit Therapeutics drug is significant. As a result, investors will want to keep close tabs on the company in the third quarter, when the full 48-week data is anticipated.

[waterloo01] 26/1/2018 09:13

“Summit reported 24-week interim data from its ezutromid Phase 2 PhaseOUT DMD study. SMMT had consistently stated that the focus at 24-weeks was the three muscle biopsy measures: utrophin intensity/distribution (target engagement), developmental myosin and muscle fiber diameter (muscle maturity). Although fat fraction (MRS) and functional assessments were also measured, preclinical models and other trials (SRPT, CATB) have demonstrated that 24-weeks is not a sufficient treatment period to expect downstream muscle health or functional improvements in DMD. We view improvements in two of the three biopsy measures as in line with our (positive) base case and an early validation of ezutromid’s ability to engage/modulate utrophin and reduce muscle damage. We raise our PT to $30 from $24 (increase probability to market by 10%, see below), and remain bullish.”

[volsung] 26/1/2018 08:42

Bought a few on the wee dip

[phowdo] 26/1/2018 08:12

Cant be long now until Sarepta make a cheeky offer to take the DMD work off Summits hands. Glynn will trade off shareholder upside on DMD side for funding of the antibiotic side.

[football] 26/1/2018 08:07

Should be opening up nearer £3 than £2

[chrisatrdg] 25/1/2018 21:58

Below is from the last update from the London Stock Exchange tonight this must surely effect the share price in the morning - are the big boys getting in or am I completely mistaken:

LAST 5 TRADES MORE REFRESH
Time/Date Price Currency Volume Trade Value* Type MIC Code Trade Type Flags
17:08:36 215.00 GBX 94,500 203,175.00 Off-book XOFF LRGS Black - Mid Point
16:27:16 215.00 GBX 25,000 53,750.00 Off-book AIMX LRGS Black - Mid Point

16:26:54 220.00 GBX 25,000 55,000.00 OFF-BOOK AIMX LRGS BLUE - BUY
16:25:31 216.59 GBX 70,000 151,612.30 OFF-BOOK AIMX LRGS BLUE - BUY

16:22:47 212.00 GBX 15,000 31,800.00 Off-book AIMX LRGS Red - Sell
* For instruments denominated in GBX, the Trade value is shown in GBP when the traded currency is GBX or GBP. When the

[chrisatrdg] 25/1/2018 21:36

Summit Therapeutics (SMMT) PhaseOutDMD: Review Of Interim 24-Week Data - Slideshow

[rhines] 25/1/2018 21:06

Hopefully more ii's will take a look over the coming weeks. The movement in AIM shares just seems to be private investors jumping from share to share. Disappointed also because had the news have been bad today the share price would be 50% down now. Not sure it's worth the risk sometimes.

[luminoso] 25/1/2018 20:44

For the only DMD drug that actually appears to work, this is not an impressive share price reaction, both here and in US. Some seemed to use the news as an opportunity to get out, de risk, whatever, hopefully tomorrow will see further gains as the news sinks in and minds turn to the likely bid from SRPT. Certainly derisks Summit as an investment.

[tilly99] 25/1/2018 20:20

Good boy!!

[waterloo01] 25/1/2018 19:42

Already partly own two of them.....X

[tilly99] 25/1/2018 19:17

I love u WaterlooShall we sell and buy IMM and spsy?

[waterloo01] 25/1/2018 18:52

We really should be flying (sp wise). 1st treatment for the 83% of boys who don;t have exon 53. If it shows it can reverse muscle damage all the better as opens up older boys who have no options.

Gene editing also won't be straightforward.




The Solid Biosciences initial public offering scheduled for Thursday suffered a potential setback when the company disclosed in a regulatory filing that there is a partial clinical hold involving its critical early-stage clinical trial of a gene-therapy treatment for Duchenne muscular dystrophy, a fatal muscle-wasting genetic disease affecting between 10,000 and 15,000 boys and young men in the U.S.

[gclark] 25/1/2018 18:17

hi abergele, I wouldn't know about that. I work in the pharma sector but am not a medical doctor or scientist. I have been involved with market access, and increasingly take an interest in clinical trial design and results.

[abergele] 25/1/2018 18:14

WONDERFUL NEWS THOUGH...gla lth's

[abergele] 25/1/2018 18:06

Could it be pos. that the drug could and would be of benefit to MND.(MotorNueron)
as a pal of mine had muscle loss with this,excuse my ignorance over the pairing of the two illnesses..? tia.

[gclark] 25/1/2018 18:04

Don't you think that Sarepta have to make an offer for Summit or the DMD drug? DMD is the main raison d'etre for Sarepta at the moment, and they can't afford to lose ezutromid, I would have thought.

[waterloo01] 25/1/2018 16:41

At 24 weeks, treatment with ezutromid led to a “meaningful” reduction in muscle damage, measured in a 23% decrease in mean developmental myosin—a biomarker of muscle damage—in a muscle biopsy compared to baseline. Two-thirds, or 14 out of 22, patients experienced a decrease in developmental myosin. And the mean level of utrophin jumped 7% compared to baseline.

“The significant reduction in muscle damage coupled with the increase in utrophin expression […] is very encouraging as it suggests ezutromid may slow the relentless cycle of muscle fibre degeneration and regeneration that is a hallmark of DMD,” said Francesco Muntoni, director of the Dubowitz Neuromuscular Centre, at the UCL Institute of Child Health and Great Ormond Street Hospital for Children in London, in the statement. “These favourable interim results are certainly a step forward in the development of utrophin modulation as a treatment approach for this fatal disease in all patients with DMD.”

[hugus maximus] 25/1/2018 16:08

Looking good.

[ohsod1t] 25/1/2018 15:53

States are recovering.......

[hugus maximus] 25/1/2018 14:32

Me too OHSODIT ... but perhaps the NASDAQ will drive things ... £ / $ rate isn't as much in our favour as it was a few weeks ago. For example a £3 share price here needs $22.2 on the NASDAQ today. If you'd have told me yesterday that we'd see these sorts of 24 wk results, I would have anticipated such news finding £3 but we'll see?